预约演示
更新于：2026-04-25
Sotrovimab
更新于：2026-04-25
概要
基本信息
药物类型 单克隆抗体 |
别名 Sotrovimab(Genetical Recombination)、sotrovimab(r-INN)、GSK4182136 + [4] |
作用方式 抑制剂 |
作用机制 SARS-CoV-2 S protein抑制剂(冠状病毒刺突糖蛋白抑制剂) |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-26), |
最高研发阶段(中国)- |
特殊审评紧急使用授权 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 569644962L
来源: *****
Sequence Code 616715821H
来源: *****
关联
28
项与 Sotrovimab 相关的临床试验CTIS2024-514071-17-00
Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies
开始日期2022-09-13 |
申办/合作机构- |
NCT05305651
Prospective Cohort Study to Monitor the Emergence of SARS-CoV-2 Spike Viral Variants in Immunocompromised Non-hospitalized Patients Exposed to Sotrovimab in Great Britain: LUNAR Study
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization and/or death when administered as early treatment in non-hospitalized patients that are at risk for progression to severe disease. Immunocompromised (IC) patients are prioritized to receive early treatment for COVID-19 as they are at high risk of disease progression, and because of their potential for prolonged viral shedding and the resulting increased risk of emergent viral mutations and potential onward community transmission.
This genomic surveillance study will aim to describe changes in the SARS-CoV-2 spike protein observed in IC participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.
This genomic surveillance study will aim to describe changes in the SARS-CoV-2 spike protein observed in IC participants receiving sotrovimab as standard of clinical care in sentinel sites at a national level to assess potential emergence of viral variants.
开始日期2022-07-01 |
申办/合作机构 |
ISRCTN74418247
Prospective cohort study to monitor the emergence of SARS-CoV-2 spike viral variants in immunocompromised non-hospitalised patients exposed to sotrovimab in Great Britain: the LUNAR study
开始日期2022-06-21 |
申办/合作机构- |
100 项与 Sotrovimab 相关的临床结果
登录后查看更多信息
100 项与 Sotrovimab 相关的转化医学
登录后查看更多信息
100 项与 Sotrovimab 相关的专利（医药）
登录后查看更多信息
283
项与 Sotrovimab 相关的文献（医药）2026-02-01·JOURNAL OF THEORETICAL BIOLOGY
Antibody escape of SARS-CoV-2 variants of concern on receptor-binding domain: A computational approach
Article
作者: Tuong, Lam-Truong ; Tran, Van-Thanh ; Le, Minh-Tri ; Thai, Khac-Minh ; Nguyen, Dac-Nhan ; Tran, Viet-Hung ; Hoai Huynh, Phuong Nguyen ; Dang, Thoai-My ; Tran-Thi, Phuong-Uyen ; Nguyen, Quoc-Thai
The receptor-binding domain (RBD) of the spike protein is a critical functional component responsible for binding between the SARS-CoV-2 and the ACE2 receptor, as well as monoclonal antibodies. This research focuses on evaluating the ability of SARS-CoV-2 variants to reduce or evade neutralizing antibody responses. The RBD structures of wild type, Delta, and Omicron structures along with nine RBD-directed antibodies downloaded from the Protein Data Bank were subjected to docking simulations via the HADDOCK 2.4 server to calculate Haddock score, binding affinity (ΔG) and dissociation constant (Kd). The resulting complexes underwent molecular dynamics simulations for 100 ns using GROMACS, and the binding free energy was calculated using gmx_MMPBSA. The findings indicated that the L452R and T478K mutations in Delta, as well as the K417N, E484A, S477N, and Q493R mutations in Omicron, were predicted to be pivotal factors in the interaction with antibodies. Omicron exhibited a greater potential for immune evasion compared to Delta. Notably, the Sotrovimab antibody demonstrated robust interactions with both variants. Etesevimab exhibited strong binding with Delta but displayed a weaker connection with Omicron. Therefore, Sotrovimab and Etesevimab remain promising candidates for in vitro and in vivo testing against SARS-CoV-2 variants.
2026-01-02·Infectious Diseases
Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study
Article
作者: Sardanelli, Alessia ; Gentile, Ivan ; Annunziata, Mario ; Trucillo, Emilia ; Cattaneo, Letizia ; Pietroluongo, Daria ; Foggia, Maria ; Grimaldi, Francesco ; di Bernardo, Salvatore ; D’Agostino, Alessia ; Buonomo, Antonio Riccardo ; Viceconte, Giulio
BACKGROUND:
The combination of antivirals and monoclonal antibodies (mAbs) in the first phase of COVID-19 has demonstrated to reduce time to viral clearance, but the superiority of combination compared to antiviral monotherapy is still debated.
RESEARCH DESIGN AND METHODS:
In an observational, prospective study, we enrolled immunocompromised outpatients with mild-to-moderate COVID-19 treated with one antiviral monotherapy within 7 days from symptoms onset, with or without sotrovimab from January 1, 2024 to October 31, 2024, and we compared them to an identical cohort of patients treated with a combination of one antiviral and sotrovimab, from May 1, 2023 to December 30, 2023. 1st of May 2023 and 31st of October 2024. Sotrovimab administered until the end of October 2023 was considered to be presumably effective against the circulating viral variants, based on virological reports.
RESULTS:
We enrolled considered 98 patients treated with nirmatrelvir/ritonavir or remdesivir. Sotrovimab was co-administered in 50/98 cases. All the patients cleared SARS-CoV-2 infection within a median of 17 (IQR 10-22) days. At the multivariate Cox regression analysis, therapy administration within 3 days from symptoms' onset (aHR 1.68; p = 0.031) and presumed sotrovimab effectiveness (aHR 1.75; p = 0.02) were found to be independent factors associated with for shorter time to viral clearance.
CONCLUSIONS:
The timing of administration of early antiviral therapy is crucial to reduce SARS-CoV-2 infection duration in immunocompromised patients and the combination with a mAb is associated with earlier viral clearance, as long asmAb is chosen among those effective against circulating variants.
2026-01-01·BIOPHYSICAL JOURNAL
An integrated multiscale computational framework deciphers SARS-CoV-2 resistance to sotrovimab
Article
作者: Tripathi, Timir ; Kar, Rajiv K ; Sharma, Akshit ; Padhi, Aditya K ; Maurya, Shweata ; Kumar, Shivank
The emergence of resistance mutations in the SARS-CoV-2 spike (S) protein presents a challenge for monoclonal antibody treatments like sotrovimab. Understanding the structural, dynamic, and molecular features of these mutations is essential for therapeutic advancements. However, the intricate landscape of potential mutations and critical residues conferring resistance to mAbs like sotrovimab remains elusive. This study introduces an integrated framework that combines interface protein design, machine learning, hybrid quantum mechanics/molecular mechanics methodologies, all-atom and coarse-grained molecular dynamics simulations, and correlation analysis. Beginning with the interface-based design and analysis, this framework elucidates the interaction between sotrovimab and the S-protein, identifying pivotal residues and plausible resistance mutations. Machine learning algorithms then facilitate the identification of potential resistance mutations using structural-sequence-binding affinity-energetics features. The hybrid quantum mechanics/molecular mechanics approach subsequently evaluates the role of mutational residues as quantum regions, assessing their impact on stabilizing the macromolecular complex. To gain a deeper understanding of the dynamic behavior of these mutations, multiscale simulations comprising all-atom and coarse-grained molecular dynamics simulations were performed, revealing their structural, biophysical and energetic impacts. These simulations complemented the static predictions, capturing the conformational dynamics and stability of the mutants in presence of glycan in the S-protein. The accuracy of the predictions is validated by correlating identified resistance mutations with clinical-sequencing data and empirical evidence from sotrovimab-treated patients. Notably, two residues, E340 at the S-protein-sotrovimab interface and Y508 distal from it, and their designs, align with clinically observed resistance mutations. Furthermore, machine learning approaches predict novel S-protein sequences with enhanced/reduced affinity for sotrovimab, validated structurally using AlphaFold. This integrated framework showcases its effectiveness in identifying potential resistance mutations, corroborated with clinical insights and offering a multidimensional strategy for decoding resistance mutations in SARS-CoV-2. Its translational relevance extends to understanding resistance mechanisms and designing novel antibody therapeutics in other systems.
225
项与 Sotrovimab 相关的新闻（医药）2026-04-04
·抗体君
抗体君感恩您的一路相伴
Let's start learning now
做事，做好事，事做好，好做事
Q8501 抗体药物靶点有哪些类型？
抗体药物靶点按功能和分布可分为六大类：
免疫检查点（如PD-1、PD-L1、CTLA-4），通过调控免疫细胞活性发挥抗肿瘤或免疫调节作用；
肿瘤相关抗原（如HER2、EGFR、CD20），在肿瘤细胞表面高表达，介导抗体依赖的细胞毒性；
细胞因子及受体（如TNF-α、IL-6R、IL-17），中和炎性因子治疗自身免疫病；
血管生成因子（如VEGF），抑制肿瘤血管生成；神经系统靶点（如CGRP、Aβ），治疗偏头痛和阿尔茨海默病；
代谢与心血管靶点（如PCSK9），调节血脂代谢。目前全球已上市抗体药物靶点超过80个，在研靶点超过200个，呈持续拓展态势，覆盖肿瘤、自身免疫、感染、神经、代谢等多个疾病领域，为患者提供了多样化的治疗选择。
♀抗体君♀
Q8502 PD-1靶点介绍及代表药物？
PD-1（程序性死亡受体-1）是表达于活化T细胞、B细胞、NK细胞表面的抑制性受体，属于CD28家族。其配体PD-L1和PD-L2表达于肿瘤细胞、抗原呈递细胞及正常组织。
PD-1与配体结合后，通过招募SHP-2磷酸酶抑制T细胞受体信号通路，诱导T细胞耗竭和凋亡，是肿瘤免疫逃逸的核心机制。靶向PD-1的抗体通过阻断PD-1与配体结合，恢复T细胞抗肿瘤活性，激活内源性免疫应答。可治疗的疾病包括黑色素瘤、非小细胞肺癌、肾细胞癌、霍奇金淋巴瘤、头颈部鳞癌、肝癌、胃癌、食管癌、尿路上皮癌、结直肠癌（MSI-H）等数十种实体瘤和血液肿瘤。
代表药物：帕博利珠单抗（Keytruda）、纳武利尤单抗（Opdivo）、信迪利单抗（Tyvyt）、特瑞普利单抗（拓益）、卡瑞利珠单抗（艾瑞卡）、替雷利珠单抗（百泽安）。
♀抗体君♀
Q8503 PD-L1靶点介绍及代表药物？
PD-L1（程序性死亡配体-1）是PD-1的主要配体，表达于肿瘤细胞、巨噬细胞、树突状细胞及多种正常组织。在肿瘤微环境中，肿瘤细胞通过高表达PD-L1与T细胞表面PD-1结合，传递抑制信号，逃避免疫监视。PD-L1抗体通过阻断PD-1/PD-L1相互作用，解除肿瘤对T细胞的抑制作用，同时可能通过抗体依赖的细胞毒性（ADCC）清除PD-L1阳性肿瘤细胞。与PD-1抗体相比，PD-L1抗体保留PD-L2/PD-1通路，理论上可能降低自身免疫副作用的发生率和严重程度。
可治疗的疾病包括非小细胞肺癌、尿路上皮癌、三阴性乳腺癌、食管鳞癌、肝癌、小细胞肺癌、宫颈癌、黑色素瘤等。
代表药物：阿替利珠单抗（Tecentriq）、度伐利尤单抗（Imfinzi）、阿维鲁单抗（Bavencio）、恩沃利单抗（恩维达）、舒格利单抗（择捷美）。
♀抗体君♀
Q8504 CTLA-4靶点介绍及代表药物？
CTLA-4（细胞毒性T淋巴细胞相关蛋白-4）是表达于活化T细胞表面的抑制性受体，与CD28竞争结合抗原呈递细胞上的B7分子（CD80/CD86）。CTLA-4亲和力显著高于CD28，传递抑制信号，在T细胞活化的早期阶段发挥“刹车”作用，防止T细胞过度活化。CTLA-4抗体通过阻断CTLA-4与B7结合，增强T细胞初始活化，扩增T细胞库，增加肿瘤浸润T细胞数量，作用机制与PD-1抗体互补。由于作用广泛，CTLA-4抗体的免疫相关不良反应发生率较高，需密切监测。
可治疗的疾病包括黑色素瘤、肾细胞癌、结直肠癌（MSI-H）、肝细胞癌、非小细胞肺癌（联合治疗）。
代表药物：伊匹木单抗（Yervoy），常与纳武利尤单抗联合用于多种肿瘤，是首个获批的免疫检查点抑制剂，开创了肿瘤免疫治疗新时代。
♀抗体君♀
Q8505 LAG-3靶点介绍及代表药物？
LAG-3（淋巴细胞活化基因-3）是表达于活化T细胞、调节性T细胞、NK细胞表面的抑制性受体，结构与CD4同源，主要配体为MHC II类分子。LAG-3与PD-1常共表达于耗竭T细胞，协同抑制T细胞功能，是继PD-1/CTLA-4之后最具潜力的免疫检查点。LAG-3抗体通过阻断LAG-3与MHC II结合，逆转T细胞耗竭，增强抗肿瘤免疫应答，与PD-1抗体联用具有协同增效作用，在PD-1耐药患者中仍可获益。可治疗的疾病包括黑色素瘤、非小细胞肺癌、肾细胞癌、胃癌、食管癌、头颈部鳞癌等实体瘤。
代表药物：瑞拉利单抗（Opdualag），是与纳武利尤单抗联合的固定剂量复方制剂，是全球首个获批的LAG-3抗体，用于治疗不可切除或转移性黑色素瘤，标志着免疫检查点抑制剂进入双靶点联合新时代。
♀抗体君♀
Q8506 TIGIT靶点介绍及代表药物？
TIGIT（T细胞免疫球蛋白和ITIM结构域蛋白）是表达于T细胞、NK细胞表面的抑制性受体，主要配体为CD155（PVR）和CD112（PVRL2），表达于肿瘤细胞和抗原呈递细胞。TIGIT与共刺激受体CD226竞争结合CD155，TIGIT结合后通过ITIM基传递抑制信号，抑制T细胞和NK细胞功能，促进调节性T细胞扩增。TIGIT抗体通过阻断TIGIT/CD155相互作用，恢复T细胞和NK细胞的抗肿瘤活性，与PD-1/PD-L1抗体联用具有协同作用。可治疗的疾病包括非小细胞肺癌、食管鳞癌、胃癌、宫颈癌、头颈部鳞癌等实体瘤。
代表药物：Tiragolumab（罗氏），在非小细胞肺癌中与阿替利珠单抗联合显示疗效提升，但部分III期研究未达主要终点，该靶点仍在探索中；Vibostolimab（默克）、Domvanalimab（吉利德）等处于临床开发阶段。
♀抗体君♀
Q8507 HER2靶点介绍及代表药物？
HER2（人表皮生长因子受体-2）是表皮生长因子受体家族成员，无已知天然配体，通过与其他HER家族成员形成异源二聚体激活下游信号通路（PI3K/AKT、MAPK），促进细胞增殖、存活和转移。约15%-20%的乳腺癌、胃癌、食管癌存在HER2基因扩增或蛋白过表达，与预后不良相关。HER2抗体通过双重机制发挥作用：直接阻断HER2二聚化抑制信号通路；通过ADCC诱导免疫细胞杀伤肿瘤细胞。可治疗的疾病包括HER2阳性乳腺癌（辅助、新辅助、晚期治疗）、HER2阳性胃癌/胃食管交界腺癌、HER2阳性结直肠癌（罕见）。
代表药物：曲妥珠单抗（Herceptin），是首个获批的HER2抗体，显著改善了HER2阳性乳腺癌预后；帕妥珠单抗（Perjeta）与曲妥珠单抗联合增强疗效；伊尼妥单抗（赛普汀）是中国自主研发；马吉妥昔单抗（Margenza）是Fc段优化的新一代抗体。
♀抗体君♀
Q8508 EGFR靶点介绍及代表药物？
EGFR（表皮生长因子受体）是受体酪氨酸激酶家族成员，配体包括EGF、TGF-α等。配体结合后诱导受体二聚化，激活下游RAS/RAF/MEK/ERK和PI3K/AKT通路，调控细胞增殖、存活、分化和血管生成。EGFR在多种实体瘤中过表达或突变，与肿瘤进展和耐药相关。EGFR抗体竞争性结合EGFR胞外域，阻断配体结合和受体活化，同时诱导ADCC效应。与EGFR小分子抑制剂不同，抗体主要作用于胞外域，对激酶区突变（如T790M）仍有效。可治疗的疾病包括转移性结直肠癌（RAS野生型）、头颈部鳞癌（局部晚期或转移性）。
代表药物：西妥昔单抗（Erbitux），是首个获批的EGFR抗体；帕尼单抗（Vectibix）为全人源EGFR抗体，免疫原性更低；尼妥珠单抗（泰欣生）是中国自主研发，用于鼻咽癌和头颈部鳞癌。
♀抗体君♀
Q8509 CD20靶点介绍及代表药物？
CD20是表达于B细胞表面的四次跨膜磷蛋白，从前B细胞到成熟B细胞表达，但浆细胞不表达。CD20参与B细胞受体信号传导和钙离子通道调节，是B细胞淋巴瘤的理想靶点，因其在B细胞肿瘤中稳定表达且不内化。CD20抗体通过多种机制清除B细胞：ADCC（NK细胞介导）、CDC（补体依赖细胞毒性）和直接诱导凋亡。不同代次CD20抗体在Fc段改造、糖基化修饰等方面优化，提升效应功能。可治疗的疾病包括非霍奇金淋巴瘤（弥漫大B细胞淋巴瘤、滤泡性淋巴瘤）、慢性淋巴细胞白血病、类风湿关节炎（部分药物）。
代表药物：利妥昔单抗（Rituxan）是首个获批的CD20抗体，开创了淋巴瘤免疫治疗时代；奥妥珠单抗（Gazyva）为糖基化修饰的II型抗体，增强ADCC和直接凋亡；奥法木单抗（Arzerra）为全人源抗体；瑞帕妥单抗（安平希）是中国自主研发。
♀抗体君♀
Q8510 CD38靶点介绍及代表药物？
CD38是表达于浆细胞、NK细胞、髓系细胞表面的II型跨膜糖蛋白，具有ADP-核糖环化酶和cADPR水解酶活性，参与细胞内钙稳态调节和细胞黏附。在多发性骨髓瘤细胞中CD38呈高表达，是治疗浆细胞肿瘤的理想靶点。CD38抗体通过多重机制清除肿瘤细胞：ADCC、ADCP（抗体依赖细胞吞噬）、CDC、直接诱导凋亡，以及通过清除CD38阳性调节性T细胞和髓源性抑制细胞改善免疫微环境。可治疗的疾病包括多发性骨髓瘤（复发/难治、新诊断、维持治疗）、轻链淀粉样变性。
代表药物：达雷妥尤单抗（Darzalex）是全球首个CD38抗体，显著改善了多发性骨髓瘤患者的预后，已成为一线治疗基石；伊莎妥昔单抗（Sarclisa）是第二个获批的CD38抗体，与卡非佐米联合用于复发/难治性多发性骨髓瘤。
♀抗体君♀
Q8511 CD19靶点介绍及代表药物？
CD19是表达于B细胞表面的跨膜糖蛋白，从前B细胞到成熟B细胞广泛表达，浆细胞不表达。CD19是B细胞受体复合物的共受体，参与B细胞活化、增殖和分化。CD19在大多数B细胞淋巴瘤和白血病中高表达，且不脱落，是CAR-T治疗的经典靶点。CD19抗体通过ADCC、CDC机制清除B细胞肿瘤，与化疗联合用于B细胞淋巴瘤。此外，CD19是CAR-T细胞疗法的核心靶点，通过基因工程改造T细胞表达抗CD19嵌合抗原受体，实现精准杀伤。可治疗的疾病包括弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、B细胞急性淋巴细胞白血病。
代表药物：Tafasitamab（Monjuvi）是CD19抗体，与来那度胺联合用于复发/难治性弥漫大B细胞淋巴瘤；贝林妥欧单抗（Blincyto）是CD19/CD3双特异性T细胞衔接器；CD19 CAR-T（Kymriah、Yescarta、奕凯达、倍诺达）在淋巴瘤和白血病中具有突破性疗效
♀抗体君♀
Q8512 BCMA靶点介绍及代表药物？
BCMA（B细胞成熟抗原）是肿瘤坏死因子受体超家族成员，表达于浆细胞和成熟B细胞，在多发性骨髓瘤细胞中呈高表达，正常组织表达有限，是骨髓瘤治疗的核心靶点。BCMA与其配体BAFF和APRIL结合，激活NF-κB通路，促进浆细胞存活和增殖。BCMA抗体通过ADCC、CDC机制清除骨髓瘤细胞；BCMA CAR-T通过基因工程改造T细胞靶向BCMA；BCMA双特异性T细胞衔接器（BiTE）同时结合T细胞CD3和骨髓瘤BCMA，实现T细胞介导的精准杀伤。可治疗的疾病包括复发/难治性多发性骨髓瘤、新诊断多发性骨髓瘤（联合治疗）。
代表药物：Belantamab mafodotin（Blenrep）是BCMA ADC，但因毒性问题撤市；Idecabtagene vicleucel（Abecma）和Ciltacabtagene autoleucel（Carvykti）是BCMA CAR-T；Teclistamab（Tecvayli）和Elranatamab（Elrexfio）是BCMA/CD3双抗，均获批用于复发/难治性多发性骨髓瘤。
♀抗体君♀
Q8513 Trop-2靶点介绍及代表药物？
Trop-2（滋养层细胞表面抗原-2）是表达于多种上皮性肿瘤的跨膜糖蛋白，参与钙离子信号传导、细胞增殖、迁移和干性维持，在正常组织中表达有限。Trop-2高表达与肿瘤进展、转移和预后不良相关。Trop-2抗体偶联药物（ADC）通过可裂解连接子将拓扑异构酶I抑制剂（SN-38）递送至肿瘤细胞，内化后释放毒素发挥强效杀伤，具有“旁观者效应”，可杀伤邻近肿瘤细胞。可治疗的疾病包括三阴性乳腺癌、HR阳性/HER2阴性乳腺癌、转移性尿路上皮癌、非小细胞肺癌、子宫内膜癌。
代表药物：戈沙妥珠单抗（Trodelvy）是全球首个获批的Trop-2 ADC，在三阴性乳腺癌中显著改善总生存期，获批用于既往接受过至少两种系统治疗的转移性三阴性乳腺癌，以及既往接受过铂类化疗和PD-1/PD-L1抑制剂的尿路上皮癌，开启了Trop-2靶向治疗新时代。
♀抗体君♀
Q8514 Nectin-4靶点介绍及代表药物？
Nectin-4（脊髓灰质炎病毒受体相关蛋白-4）是细胞黏附分子Nectin家族成员，表达于胎盘、胚胎组织，在多种实体瘤（尿路上皮癌、乳腺癌、肺癌、胰腺癌）中异常高表达，通过激活PI3K/AKT通路促进肿瘤增殖和转移。正常成人组织中表达有限，是理想的ADC靶点。Nectin-4抗体偶联药物（ADC）将微管抑制剂（MMAE）通过可裂解连接子与抗体偶联，精准递送至肿瘤细胞，内化后释放毒素诱导凋亡，具有旁观者效应。可治疗的疾病包括局部晚期或转移性尿路上皮癌（既往接受过铂类化疗和PD-1/PD-L1抑制剂），以及与帕博利珠单抗联合用于一线治疗。
代表药物：恩诺单抗（Padcev）是全球首个获批的Nectin-4 ADC，与帕博利珠单抗联合已获批为尿路上皮癌一线治疗方案，显著提升客观缓解率和总生存期，成为尿路上皮癌治疗的新标准。
♀抗体君♀
Q8515 FRα靶点介绍及代表药物？
FRα（叶酸受体α）是糖基磷脂酰肌醇锚定的膜蛋白，介导叶酸内吞。在正常组织中表达受限，而在卵巢癌、三阴性乳腺癌、非小细胞肺癌、子宫内膜癌等多种实体瘤中高表达，与肿瘤进展和化疗耐药相关。FRα的高表达使其成为ADC和CAR-T的理想靶点。FRα抗体偶联药物（ADC）通过可裂解连接子将微管抑制剂（DM4）递送至肿瘤细胞，内化后释放毒素诱导凋亡，具有旁观者效应。可治疗的疾病包括铂类耐药的上皮性卵巢癌、输卵管癌、原发性腹膜癌。
代表药物：Mirvetuximab soravtansine（Elahere）是全球首个获批的FRα ADC，在铂耐药卵巢癌中显著改善无进展生存期和总生存期，成为该类患者的新治疗选择，尤其适用于FRα高表达人群，填补了铂耐药卵巢癌治疗的空白。
♀抗体君♀
Q8516 TNF-α靶点介绍及代表药物？
TNF-α（肿瘤坏死因子-α）是主要由巨噬细胞、T细胞产生的促炎细胞因子，通过结合TNFR1和TNFR2受体激活NF-κB和MAPK通路，诱导炎症反应、细胞凋亡和免疫细胞活化。TNF-α在类风湿关节炎、炎症性肠病、银屑病、强直性脊柱炎等自身免疫病中过度产生，是驱动炎症的关键因子。TNF-α抗体通过中和可溶性和膜结合型TNF-α，阻断其与受体结合，抑制炎症级联反应，同时膜结合型TNF-α可被抗体介导的ADCC清除。可治疗的疾病包括类风湿关节炎、强直性脊柱炎、银屑病关节炎、克罗恩病、溃疡性结肠炎、幼年特发性关节炎、葡萄膜炎。
代表药物：英夫利西单抗（Remicade）是首个获批的TNF-α抗体；阿达木单抗（Humira）是全球“药王”，适应症最广泛；依那西普（Enbrel）为TNF-α受体-Fc融合蛋白；戈利木单抗（Simponi）、赛妥珠单抗（Cimzia）为新一代产品。
♀抗体君♀
Q8517 IL-6R靶点介绍及代表药物？
IL-6（白细胞介素-6）是重要的促炎细胞因子，通过结合膜结合型IL-6受体（mIL-6R）或可溶性IL-6受体（sIL-6R）与gp130形成复合物，激活JAK/STAT3通路，介导炎症、急性期反应、B细胞分化和T细胞活化。IL-6在类风湿关节炎、Castleman病、细胞因子释放综合征等疾病中显著升高。IL-6R抗体通过阻断IL-6与受体的结合，抑制下游信号通路，发挥抗炎和免疫调节作用。可治疗的疾病包括类风湿关节炎、全身型幼年特发性关节炎、Castleman病、细胞因子释放综合征、大动脉炎、巨细胞动脉炎。
代表药物：托珠单抗（Actemra）是全球首个IL-6R抗体，在COVID-19重症患者细胞因子风暴治疗中发挥了重要作用；萨瑞鲁单抗（Kevzara）为第二个获批的IL-6R抗体，用于类风湿关节炎。
♀抗体君♀
Q8518 IL-17A靶点介绍及代表药物？
IL-17A是Th17细胞、γδ T细胞产生的促炎细胞因子，通过结合IL-17RA/IL-17RC受体复合物，激活NF-κB和MAPK通路，诱导中性粒细胞募集、促炎趋化因子释放、组织破坏和骨侵蚀。IL-17A在银屑病、银屑病关节炎、强直性脊柱炎中发挥核心致病作用，驱动皮肤和关节炎症。IL-17A抗体通过中和IL-17A，阻断其与受体结合，抑制下游炎症通路，显著改善皮肤和关节症状。可治疗的疾病包括中重度斑块状银屑病、银屑病关节炎、强直性脊柱炎、放射学阴性中轴型脊柱关节炎。
代表药物：司库奇尤单抗（Cosentyx）是全球首个IL-17A抗体，在银屑病治疗中具有突破性疗效，皮损清除率高；依奇珠单抗（Taltz）为第二代产品，给药间隔更灵活；布罗利尤单抗（Siliq）因安全性问题使用受限。
♀抗体君♀
Q8519 IL-12/23靶点介绍及代表药物？
IL-12和IL-23是共享p40亚基的异源二聚体细胞因子：IL-12由p35和p40组成，促进Th1细胞分化和IFN-γ产生；IL-23由p19和p40组成，促进Th17细胞分化和IL-17产生。两者在银屑病、银屑病关节炎、炎症性肠病中发挥协同致病作用。p40抗体通过同时中和IL-12和IL-23，阻断Th1和Th17通路，发挥抗炎作用，比单靶点抗体具有更广泛的免疫调节效应。可治疗的疾病包括中重度斑块状银屑病、银屑病关节炎、克罗恩病、溃疡性结肠炎。
代表药物：乌司奴单抗（Stelara）是全球首个IL-12/23 p40抗体，在银屑病和炎症性肠病中均显示出优异疗效，给药间隔为每12周一次，具有便利性优势，是自身免疫病领域的重磅药物。
♀抗体君♀
Q8520 IL-23靶点介绍及代表药物？
IL-23是由p19和p40亚基组成的异源二聚体细胞因子，主要由巨噬细胞和树突状细胞产生，通过结合IL-23受体促进Th17细胞存活、扩增和效应功能，是银屑病、银屑病关节炎、炎症性肠病的关键驱动因子。与IL-12/23 p40抗体不同，IL-23 p19抗体特异性靶向IL-23，保留IL-12介导的抗感染免疫功能，理论上具有更优的安全性。IL-23抗体通过阻断IL-23与受体结合，抑制Th17通路，显著改善皮肤和肠道炎症。可治疗的疾病包括中重度斑块状银屑病、银屑病关节炎、克罗恩病、溃疡性结肠炎。
代表药物：古塞奇尤单抗（Tremfya）、瑞莎珠单抗（Skyrizi）、替拉珠单抗（Ilumya）。瑞莎珠单抗在银屑病治疗中显示出极高的皮损清除率（PASI 90/100），给药间隔为每12周一次，是银屑病治疗的新标杆。
♀抗体君♀
Q8521 IL-4Rα靶点介绍及代表药物？
IL-4Rα是IL-4和IL-13受体的共同亚基：IL-4结合IL-4Rα/γc或IL-4Rα/IL-13Rα1，IL-13结合IL-4Rα/IL-13Rα1，激活STAT6通路，驱动Th2型免疫应答、嗜酸性粒细胞募集、IgE产生、黏液分泌和组织重塑。IL-4Rα在特应性皮炎、哮喘、鼻息肉等2型炎症性疾病中发挥核心作用。IL-4Rα抗体通过阻断IL-4和IL-13双信号通路，全面抑制2型炎症，是Th2通路中靶点最上游、作用最广泛的生物制剂。可治疗的疾病包括中重度特应性皮炎、中重度哮喘、慢性鼻窦炎伴鼻息肉、嗜酸性粒细胞性食管炎。
代表药物：度普利尤单抗（Dupixent）是全球首个IL-4Rα抗体，在特应性皮炎和哮喘治疗中具有里程碑意义，显著改善患者生活质量，已拓展至多个2型炎症适应症。
♀抗体君♀
Q8522 IL-5靶点介绍及代表药物？
IL-5是Th2细胞、2型固有淋巴细胞产生的细胞因子，主要作用于嗜酸性粒细胞，促进其分化、成熟、活化、存活和募集。IL-5在嗜酸性粒细胞型哮喘、嗜酸性粒细胞增多症等疾病中驱动嗜酸性粒细胞炎症，是2型炎症的关键效应因子。IL-5抗体通过中和IL-5，阻断其与嗜酸性粒细胞表面受体结合，显著降低外周血和组织中嗜酸性粒细胞数量，控制嗜酸性粒细胞相关炎症。可治疗的疾病包括嗜酸性粒细胞型重度哮喘、嗜酸性粒细胞性肉芽肿性多血管炎、高嗜酸性粒细胞综合征。
代表药物：美泊利珠单抗（Nucala）是全球首个IL-5抗体，在重度哮喘中显著降低急性发作率，改善肺功能；瑞替珠单抗（Cinqair）为第二代产品，用于重度哮喘的附加维持治疗。
♀抗体君♀
Q8523 IL-5Rα靶点介绍及代表药物？
IL-5Rα是IL-5受体的特异性α亚基，主要表达于嗜酸性粒细胞和嗜碱性粒细胞表面，与IL-5结合后招募βc亚基形成高亲和力受体复合物，激活JAK/STAT通路，介导嗜酸性粒细胞增殖、分化和存活。IL-5Rα抗体通过结合嗜酸性粒细胞表面的IL-5Rα，招募NK细胞通过ADCC作用清除嗜酸性粒细胞，实现快速、持久的嗜酸性粒细胞耗竭，作用机制与IL-5抗体不同，可清除已活化的嗜酸性粒细胞。可治疗的疾病包括嗜酸性粒细胞型重度哮喘。
代表药物：贝那利珠单抗（Fasenra）通过无岩藻糖基化Fc段增强ADCC效应，单次给药后快速清除嗜酸性粒细胞，给药间隔可延长至8周，具有便利性优势，在重度哮喘治疗中显示出快速起效和持久控制的特点。
♀抗体君♀
Q8524 VEGF靶点介绍及代表药物？
VEGF（血管内皮生长因子）是关键的血管生成因子家族成员（VEGF-A、B、C、D、PlGF），通过结合VEGFR-1、VEGFR-2、VEGFR-3受体，激活RAS/MAPK和PI3K/AKT通路，促进内皮细胞增殖、迁移、存活和血管通透性。VEGF在肿瘤血管生成、湿性年龄相关性黄斑变性、糖尿病视网膜病变中发挥核心作用。VEGF抗体通过中和VEGF，阻断其与受体结合，抑制病理性血管生成和血管渗漏。可治疗的疾病包括转移性结直肠癌、非小细胞肺癌、肾细胞癌、胶质母细胞瘤、宫颈癌、卵巢癌（肿瘤）；湿性AMD、糖尿病黄斑水肿、视网膜静脉阻塞、糖尿病视网膜病变（眼科）。
代表药物：贝伐珠单抗（Avastin）是首个抗血管生成抗体药物，广泛用于多种实体瘤；雷珠单抗（Lucentis）用于眼科疾病，为眼科抗VEGF治疗的经典药物；康柏西普（朗沐）是中国自主研发的VEGF受体-Fc融合蛋白。
♀抗体君♀
Q8525 PCSK9靶点介绍及代表药物？
PCSK9（前蛋白转化酶枯草溶菌素9）是肝脏分泌的丝氨酸蛋白酶，分泌后与肝细胞表面的LDL受体结合，引导LDL受体进入溶酶体降解，减少LDL受体数量，导致血液中LDL-C清除减少、水平升高。PCSK9功能获得性突变导致家族性高胆固醇血症，功能缺失性突变则与低LDL-C和心血管风险降低相关。PCSK9抗体通过中和PCSK9，阻断其与LDL受体结合，减少LDL受体降解，增加LDL受体数量，从而增强LDL-C清除。可治疗的疾病包括家族性高胆固醇血症（纯合子、杂合子）、动脉粥样硬化性心血管疾病（二级预防）、他汀不耐受的高胆固醇血症。
代表药物：依洛尤单抗（Repatha）、阿利西尤单抗（Praluent），两者均显著降低LDL-C（50%-70%）和心血管事件风险，给药间隔为每2周或每月一次，是高胆固醇血症治疗的重大突破。
♀抗体君♀
Q8526 CGRP靶点介绍及代表药物？
CGRP（降钙素基因相关肽）是感觉神经元释放的神经肽，广泛分布于三叉神经血管系统，是强效的血管扩张剂和神经炎症调节剂。在偏头痛发作时，CGRP从三叉神经末梢释放，引起颅内血管扩张、神经源性炎症和疼痛信号传导，是偏头痛的关键介质。CGRP抗体通过中和CGRP或其受体，阻断CGRP介导的血管扩张和神经炎症，预防偏头痛发作，而非急性止痛。可治疗的疾病包括发作性偏头痛、慢性偏头痛的预防性治疗。
代表药物：Erenumab（Aimovig）靶向CGRP受体；Galcanezumab（Emgality）、Fremanezumab（Ajovy）靶向CGRP配体；Epinezumab（Vyepti）为静脉制剂。这些药物显著降低偏头痛发作频率，开创了偏头痛特异性预防治疗的新时代。
♀抗体君♀
Q8527 Aβ靶点介绍及代表药物？
Aβ（β-淀粉样蛋白）是由淀粉样前体蛋白（APP）经β-分泌酶和γ-分泌酶酶切产生的多肽片段，在阿尔茨海默病患者脑内聚集成斑块，是阿尔茨海默病的核心病理标志。Aβ寡聚体具有神经毒性，可诱导突触功能障碍、tau蛋白过度磷酸化、神经炎症和神经元死亡，是疾病进展的关键驱动因素。Aβ抗体通过结合Aβ斑块和寡聚体，招募小胶质细胞通过Fc介导的吞噬作用清除Aβ，延缓认知功能下降。可治疗的疾病包括阿尔茨海默病（轻度认知障碍、轻度痴呆）。
代表药物：仑卡奈单抗（Leqembi）是全球首个获得完全批准的Aβ抗体，在III期研究中减缓认知下降27%，标志着阿尔茨海默病治疗进入疾病修饰时代；多奈单抗（Kisunla）为第二个获批的Aβ抗体，靶向Aβ斑块，可有限疗程停药，为患者提供新选择。
♀抗体君♀
Q8528 CD3靶点介绍及代表药物？
CD3是T细胞受体复合物的核心亚基，表达于成熟T细胞表面，参与T细胞活化和信号传导。CD3抗体通过结合T细胞表面的CD3，激活T细胞，是双特异性抗体中招募T细胞的关键锚点。在双特异性T细胞衔接器（BiTE）中，CD3抗体臂与肿瘤抗原抗体臂融合，将T细胞定向至肿瘤细胞，实现精准杀伤，不依赖MHC呈递。可治疗的疾病包括B细胞急性淋巴细胞白血病（贝林妥欧单抗）、多发性骨髓瘤（Teclistamab、Elranatamab）、弥漫大B细胞淋巴瘤（Epcoritamab、Glofitamab）、滤泡性淋巴瘤等。
代表药物：贝林妥欧单抗（Blincyto）是全球首个CD3/CD19双特异性T细胞衔接器，用于复发/难治性B细胞ALL；Teclistamab（Tecvayli）为CD3/BCMA双抗，用于多发性骨髓瘤；Epcoritamab（Epkinly）和Glofitamab（Columvi）为CD3/CD20双抗，用于弥漫大B细胞淋巴瘤，均显示高缓解率。
♀抗体君♀
Q8529 CD47靶点介绍及代表药物？
CD47是广泛表达于细胞表面的“别吃我”信号分子，通过与巨噬细胞表面的SIRPα结合，抑制吞噬作用，保护正常细胞免受免疫清除。肿瘤细胞通过高表达CD47逃避免疫清除，与不良预后相关。CD47抗体通过阻断CD47/SIRPα相互作用，解除“别吃我”信号，增强巨噬细胞介导的肿瘤细胞吞噬，同时可通过ADCC和ADCP协同抗肿瘤。可治疗的疾病包括急性髓系白血病、骨髓增生异常综合征、非霍奇金淋巴瘤、实体瘤。
代表药物：Magrolimab（吉利德）是首个进入III期临床的CD47抗体，在骨髓增生异常综合征和急性髓系白血病中显示初步疗效，但因贫血等安全性问题部分研究暂停；Evorpacept（ALX Oncology）为CD47抗体-Fc融合蛋白，通过降低红细胞结合减少贫血风险，处于临床开发阶段。
♀抗体君♀
Q8530 CD73靶点介绍及代表药物？
CD73（胞外-5'-核苷酸酶）是表达于多种细胞（包括肿瘤细胞、免疫细胞、基质细胞）表面的酶，将AMP转化为腺苷，腺苷通过结合A2A受体抑制T细胞、NK细胞活性，促进调节性T细胞和髓源性抑制细胞功能，形成免疫抑制微环境。CD73在多种肿瘤中高表达，与免疫治疗耐药相关。CD73抗体通过阻断CD73酶活性，减少腺苷产生，逆转免疫抑制，增强抗肿瘤免疫应答，与PD-1/PD-L1抗体联用具有协同作用。可治疗的疾病包括非小细胞肺癌、乳腺癌、胰腺癌、结直肠癌、肾癌等实体瘤。
代表药物：Oleclumab（阿斯利康）处于临床开发阶段，与度伐利尤单抗联合用于非小细胞肺癌；Mupadolimab（Corvus）为CD73抗体；Uliledlimab（天境生物）为中国自主研发的CD73抗体，在临床研究中显示良好耐受性和初步疗效。该靶点尚无上市药物。
♀抗体君♀
Q8531 CEACAM5靶点介绍及代表药物？
CEACAM5（癌胚抗原相关细胞黏附分子5，又称CEA）是糖基化膜蛋白，在正常成人组织中表达有限，在结直肠癌、胃癌、非小细胞肺癌、胰腺癌、乳腺癌等多种实体瘤中高表达，是经典的肿瘤标志物和治疗靶点。CEACAM5参与细胞黏附、增殖和存活，高表达与预后不良相关。CEACAM5抗体偶联药物（ADC）通过将细胞毒性载荷精准递送至肿瘤细胞，内化后释放毒素发挥强效杀伤，同时避免全身毒性。可治疗的疾病包括非小细胞肺癌、结直肠癌、胃癌、胰腺癌。
代表药物：Tusamitamab ravtansine（赛诺菲）处于III期临床研究，用于非小细胞肺癌；DS-7300（第一三共）为CEACAM5 ADC，在非小细胞肺癌中显示良好疗效和可控安全性。目前尚无CEACAM5靶点抗体药物获批，多个ADC处于临床开发后期，有望成为泛癌种靶向治疗新选择。
♀抗体君♀
Q8532 GPC3靶点介绍及代表药物？
GPC3（磷脂酰肌醇蛋白聚糖-3）是锚定于细胞膜表面的硫酸乙酰肝素蛋白聚糖，在胚胎发育中表达，成人正常组织中表达受限，在肝细胞癌中特异性高表达（约70%-80%），是肝癌诊断和治疗的理想靶点。GPC3参与Wnt信号通路调节，促进肿瘤细胞增殖和存活。GPC3抗体通过ADCC、ADCP机制清除GPC3阳性肿瘤细胞；GPC3 CAR-T和双特异性抗体也处于开发中。可治疗的疾病包括肝细胞癌、肺鳞癌、卵巢癌等GPC3阳性肿瘤。
代表药物：Codrituzumab（罗氏）是首个进入临床的GPC3抗体，但III期研究未达主要终点；目前GPC3靶点的CAR-T（如科济生物CT011）处于临床开发阶段，在肝细胞癌中显示初步疗效和良好安全性；GPC3/CD3双抗也处于早期临床研究。
♀抗体君♀
Q8533 MUC1靶点介绍及代表药物？
MUC1（黏蛋白1）是跨膜黏蛋白家族成员，在正常上皮细胞表面表达，保护上皮屏障。在多种实体瘤（乳腺癌、肺癌、胰腺癌、卵巢癌、结直肠癌）中，MUC1异常过度表达、糖基化异常，暴露出肿瘤特异性表位，成为肿瘤免疫治疗的重要靶点。MUC1参与细胞信号传导、免疫逃逸和转移。MUC1抗体通过ADCC、CDC机制杀伤肿瘤细胞；MUC1 CAR-T和疫苗也在开发中。可治疗的疾病包括三阴性乳腺癌、非小细胞肺癌、胰腺癌、卵巢癌等。
代表药物：Gatipotuzumab（处于临床研究阶段）为MUC1抗体；MVA-MUC1-IL2疫苗（TG4010）用于非小细胞肺癌。目前尚无MUC1靶点抗体药物获批，该靶点开发因MUC1在正常组织表达和免疫原性挑战而进展缓慢，仍处于早期探索阶段。
♀抗体君♀
Q8534 FAP靶点介绍及代表药物？
FAP（成纤维细胞活化蛋白）是II型跨膜丝氨酸蛋白酶，在肿瘤相关成纤维细胞（CAF）表面高表达，在正常成人组织中表达极低。FAP通过其酶活性降解细胞外基质，促进肿瘤侵袭、转移和免疫抑制，是肿瘤微环境中的关键靶点。FAP抗体可用于肿瘤成像诊断，也可作为ADC或双特异性抗体的靶向臂，将治疗载荷递送至肿瘤微环境，而非直接杀伤肿瘤细胞。可治疗的疾病包括多种实体瘤（乳腺癌、肺癌、胰腺癌、结直肠癌），作为泛癌种靶向递送策略。
代表药物：FAP-IL2融合蛋白（RO6874281，罗氏）处于临床开发，将IL-2靶向递送至肿瘤微环境，激活免疫细胞；FAP-ADC（如Bayer的FAP-DM1）处于早期临床。目前尚无FAP靶点抗体药物获批，该靶点主要作为肿瘤微环境递送平台而非直接治疗靶点。
♀抗体君♀
Q8535 CA9靶点介绍及代表药物？
CA9（碳酸酐酶9）是跨膜金属酶，在缺氧条件下通过HIF-1α诱导表达，参与pH调节，维持肿瘤细胞在酸性微环境中的存活。CA9在正常组织中表达极低，在肾透明细胞癌中近乎100%表达，是肾癌的特异性靶点。CA9高表达与肿瘤侵袭、转移和预后不良相关。CA9抗体通过ADCC、CDC机制杀伤CA9阳性肿瘤细胞；CA9 ADC和CAR-T也在开发中。可治疗的疾病包括肾透明细胞癌、其他缺氧相关实体瘤。
代表药物：Girentuximab（Wilex）是CA9抗体，用于肾癌的成像诊断和治疗探索，但III期研究未达主要终点；目前CA9 CAR-T和ADC处于临床开发阶段，在肾癌中显示初步疗效，该靶点仍需进一步验证。
♀抗体君♀
Q8536 PSMA靶点介绍及代表药物？
PSMA（前列腺特异性膜抗原）是II型跨膜糖蛋白，在前列腺癌细胞表面高表达（表达量可增加100-1000倍），在前列腺癌转移灶中表达更高，是前列腺癌诊断和治疗的理想靶点。PSMA具有叶酸水解酶和神经肽酶活性，参与细胞迁移和存活。PSMA抗体可用于前列腺癌成像（PET/CT），也可作为ADC或CAR-T的靶向臂，将治疗载荷递送至前列腺癌细胞。可治疗的疾病包括转移性去势抵抗性前列腺癌、激素敏感性前列腺癌。
代表药物：Lutetium-177 PSMA-617（Pluvicto）是PSMA靶向放射性配体疗法，非抗体药物；PSMA ADC（如ARX517）处于临床开发阶段；PSMA CAR-T也处于早期临床研究。目前尚无PSMA靶点抗体药物获批，该靶点主要以放射性配体和小分子药物为主。
♀抗体君♀
Q8537 RSV靶点介绍及代表药物？
RSV（呼吸道合胞病毒）融合蛋白（F蛋白）是RSV病毒包膜上的糖蛋白，介导病毒与宿主细胞膜融合及病毒进入，是RSV中和抗体的主要靶点。F蛋白在RSV A和B亚型中高度保守。RSV抗体通过结合F蛋白的融合前构象（pre-F），阻断病毒与细胞膜融合，中和病毒，预防RSV感染。可治疗的疾病包括RSV感染预防（呼吸道合胞病毒下呼吸道疾病）。
代表药物：帕利珠单抗（Synagis）是全球首个RSV抗体，用于高危婴幼儿（早产儿、先天性心脏病、慢性肺病）的RSV季节性预防；Nirsevimab（Beyfortus）是长效RSV抗体，通过Fc工程延长半衰期，单次给药覆盖整个RSV季节，已获批用于所有婴幼儿的RSV预防，是RSV预防的重大突破。
♀抗体君♀
Q8538 SARS-CoV-2靶点介绍及代表药物？
SARS-CoV-2刺突蛋白（Spike蛋白）是病毒表面糖蛋白，通过其受体结合域（RBD）与宿主细胞ACE2受体结合，介导病毒进入，是新冠病毒中和抗体的主要靶点。刺突蛋白在病毒变异过程中不断突变，导致抗体中和活性下降。SARS-CoV-2抗体通过结合刺突蛋白RBD区域，阻断与ACE2结合，中和病毒，预防和治疗COVID-19。
可治疗的疾病包括COVID-19的预防（暴露前/暴露后预防）和治疗（轻中症高风险患者）。代表药物：Casirivimab/imdevimab（REGEN-COV）、Bamlanivimab/etesevimab、Sotrovimab、Tixagevimab/cilgavimab（Evusheld）等，但因病毒变异导致大部分抗体失效，目前多数已撤市或限制使用，仅少数对特定变异株仍有活性。
♀抗体君♀
Q8539 C5靶点介绍及代表药物？
C5是补体系统级联反应的关键组分，在补体活化后裂解为C5a（强效过敏毒素）和C5b（启动膜攻击复合物形成），介导炎症、细胞溶解和组织损伤。补体过度活化在阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征、重症肌无力等疾病中发挥核心致病作用。C5抗体通过结合C5，阻断其裂解，抑制补体级联反应下游通路，减少炎症和细胞损伤。可治疗的疾病包括阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征、抗乙酰胆碱受体抗体阳性的全身型重症肌无力、视神经脊髓炎谱系疾病。
代表药物：依库珠单抗（Soliris）是全球首个C5抗体，开创了补体靶向治疗新时代；瑞利珠单抗（Ultomiris）为长效C5抗体，给药间隔延长至8周，提高了患者便利性；Crovalimab（派圣凯）是中国自主研发的可皮下给药C5抗体。
♀抗体君♀
Q8540 CGRP受体靶点介绍及代表药物？
CGRP受体是由降钙素受体样受体（CLR）和受体活性修饰蛋白1（RAMP1）组成的异源二聚体，表达于三叉神经节、脑血管平滑肌等组织。CGRP与其受体结合后，激活cAMP通路，引起血管扩张、神经炎症和疼痛信号传导，是偏头痛的关键介质。CGRP受体抗体通过结合CGRP受体，阻断CGRP与其受体的相互作用，抑制下游信号通路，预防偏头痛发作。可治疗的疾病包括发作性偏头痛、慢性偏头痛的预防性治疗。
代表药物：Erenumab（Aimovig）是全球首个靶向CGRP受体的全人源抗体，通过阻断CGRP与受体结合，显著降低偏头痛发作频率，给药方式为每月一次皮下注射，是偏头痛预防性治疗的里程碑药物，与靶向CGRP配体的抗体共同开创了偏头痛特异性预防治疗新时代。
♀抗体君♀
Q8541 IL-1RAP靶点介绍及代表药物？
IL-1RAP（IL-1受体辅助蛋白）是IL-1信号通路的关键共受体，与IL-1RI结合形成高亲和力受体复合物，介导IL-1α、IL-1β和IL-1Ra的信号传导。IL-1RAP在多种炎症性疾病和肿瘤中表达上调，是抗炎和抗肿瘤的双重靶点。IL-1RAP抗体通过阻断IL-1RAP与IL-1RI的相互作用，抑制IL-1信号通路，同时可通过ADCC清除IL-1RAP阳性肿瘤细胞。可治疗的疾病包括IL-1相关自身炎症性疾病（如痛风、家族性地中海热）、髓系白血病（临床前）。
代表药物：尚无IL-1RAP抗体获批上市，CAN04处于临床开发阶段，用于非小细胞肺癌、胰腺癌等实体瘤与化疗联合治疗，该靶点尚在探索中，主要作为IL-1通路调控和肿瘤免疫治疗的双重靶点。
♀抗体君♀
Q8542 GM-CSF靶点介绍及代表药物？
GM-CSF（粒细胞-巨噬细胞集落刺激因子）是主要由T细胞、巨噬细胞、成纤维细胞产生的细胞因子，促进髓系细胞（中性粒细胞、巨噬细胞、树突状细胞）分化、活化和存活。GM-CSF在类风湿关节炎、多发性硬化等自身免疫病中驱动炎症反应，尤其是巨噬细胞和中性粒细胞介导的组织损伤。GM-CSF抗体通过中和GM-CSF，抑制髓系细胞活化，减少炎症因子释放，发挥抗炎作用。可治疗的疾病包括类风湿关节炎、COVID-19相关过度炎症。
代表药物：奥替利单抗（Otilimab，葛兰素史克），在类风湿关节炎III期研究中显示一定疗效但未达主要终点；伦泽鲁单抗（Lenzilumab）用于COVID-19治疗，该靶点抗体药物尚未有重磅产品上市，仍需更多临床验证。
♀抗体君♀
Q8543 IFN-γ靶点介绍及代表药物？
IFN-γ（干扰素-γ）是Th1细胞、CTL、NK细胞产生的关键促炎细胞因子，通过激活JAK/STAT1通路，诱导M1型巨噬细胞极化、MHC分子上调、T细胞活化和炎症反应。IFN-γ在噬血细胞性淋巴组织细胞增多症、巨噬细胞活化综合征、移植物抗宿主病等过度炎症状态中发挥核心致病作用，可导致危及生命的全身性炎症。IFN-γ抗体通过中和IFN-γ，阻断其与受体结合，抑制下游炎症通路，快速控制过度炎症反应。可治疗的疾病包括噬血细胞性淋巴组织细胞增多症、巨噬细胞活化综合征、成人Still病。
代表药物：依帕伐单抗（Gamifant）是全球首个获批的IFN-γ抗体，用于治疗难治性、复发性或进展性噬血细胞性淋巴组织细胞增多症，填补了该罕见病治疗空白，显著改善患者预后。
♀抗体君♀
Q8544 IL-36R靶点介绍及代表药物？
IL-36R（IL-36受体）是IL-1受体家族成员，其配体IL-36α、β、γ在皮肤中高表达，通过激活NF-κB和MAPK通路，驱动中性粒细胞浸润、角质形成细胞增殖和炎症因子释放。IL-36通路在泛发性脓疱型银屑病中发挥核心致病作用，该病是一种罕见但严重的自身炎症性皮肤病。IL-36R抗体通过阻断IL-36与受体的结合，抑制下游炎症通路，快速控制皮肤脓疱和全身炎症反应。可治疗的疾病包括泛发性脓疱型银屑病（急性发作期）。
代表药物：佩索利单抗（Spevigo）是全球首个IL-36R抗体，获批用于泛发性脓疱型银屑病的急性发作治疗，单次给药可快速清除脓疱，是该罕见病的首个靶向治疗药物，具有突破性临床价值。
♀抗体君♀
Q8545 CD19靶点介绍及代表药物？
CD19是表达于B细胞表面的跨膜糖蛋白，从前B细胞到成熟B细胞广泛表达，浆细胞不表达。CD19是B细胞受体复合物的共受体，参与B细胞活化、增殖和分化。CD19在大多数B细胞淋巴瘤和白血病中高表达，在自身免疫病中B细胞异常活化也发挥重要作用。CD19抗体通过ADCC、CDC机制清除B细胞，用于治疗B细胞介导的自身免疫病和B细胞肿瘤。可治疗的疾病包括系统性红斑狼疮、类风湿关节炎（自身免疫）；弥漫大B细胞淋巴瘤、滤泡性淋巴瘤（肿瘤）。
代表药物：Inebilizumab（Uplizna）是CD19抗体，用于视神经脊髓炎谱系疾病，通过耗竭CD19阳性B细胞和浆细胞，减少致病性自身抗体产生；Tafasitamab（Monjuvi）用于淋巴瘤治疗。
♀抗体君♀
Q8546 BAFF靶点介绍及代表药物？
BAFF（B细胞活化因子）是TNF家族成员，由单核细胞、树突状细胞、T细胞产生，通过结合BAFF-R、BCMA、TACI受体，促进B细胞存活、成熟和分化。BAFF过表达与系统性红斑狼疮、干燥综合征、类风湿关节炎等自身免疫病中B细胞过度活化相关。BAFF抗体通过中和BAFF，减少BAFF介导的B细胞存活信号，促进自身反应性B细胞凋亡，降低自身抗体水平。可治疗的疾病包括系统性红斑狼疮、干燥综合征、IgG4相关疾病等。
代表药物：贝利尤单抗（Benlysta）是全球首个BAFF抗体，获批用于系统性红斑狼疮，显著改善疾病活动度，减少激素用量，是狼疮治疗的重大突破；泰它西普（泰爱）是中国自主研发的BAFF/APRIL双靶向融合蛋白，也获批用于系统性红斑狼疮。
♀抗体君♀
Q8547 CD40L靶点介绍及代表药物？
CD40L（CD154）是表达于活化T细胞、血小板表面的TNF家族成员，与B细胞、树突状细胞、巨噬细胞上的CD40结合，介导T细胞与抗原呈递细胞相互作用，促进B细胞活化、抗体类别转换、生发中心形成和记忆B细胞产生。CD40L过表达与系统性红斑狼疮、干燥综合征、移植物抗宿主病等自身免疫病相关。CD40L抗体通过阻断CD40L/CD40相互作用，抑制T细胞依赖的B细胞活化，减少自身抗体产生，调节免疫应答。可治疗的疾病包括系统性红斑狼疮、干燥综合征、移植物抗宿主病、血小板减少症等。
代表药物：Dapirolizumab pegol（UCB）处于临床开发阶段；Ruplizumab（已撤市）因血栓风险受限。该靶点因血栓安全性问题开发受阻，新一代分子通过Fc工程或片段化降低风险。
♀抗体君♀
Q8548 α4β7整合素靶点介绍及代表药物？
α4β7整合素是表达于T细胞表面的黏附分子，与肠道血管内皮细胞上的MAdCAM-1结合，介导T细胞向肠道组织的归巢。在炎症性肠病（克罗恩病、溃疡性结肠炎）中，活化的T细胞通过α4β7整合素异常归巢至肠道，驱动肠道炎症。α4β7整合素抗体通过阻断α4β7与MAdCAM-1的相互作用，抑制T细胞向肠道的归巢，减少肠道局部炎症反应，而不影响全身免疫。可治疗的疾病包括中重度溃疡性结肠炎、克罗恩病。
代表药物：维得利珠单抗（Entyvio）是全球首个α4β7整合素抗体，选择性作用于肠道，具有肠道特异性，避免了全身性免疫抑制的副作用，在炎症性肠病治疗中具有重要地位，是溃疡性结肠炎和克罗恩病的一线生物制剂。
♀抗体君♀
Q8549 IL-23靶点介绍及代表药物？
IL-23是由p19和p40亚基组成的异源二聚体细胞因子，主要由巨噬细胞和树突状细胞产生，通过结合IL-23受体促进Th17细胞存活、扩增和效应功能。IL-23在银屑病、银屑病关节炎、炎症性肠病中发挥核心致病作用，是驱动Th17通路的上游关键因子。IL-23抗体通过特异性中和IL-23（p19亚基），阻断Th17通路，保留IL-12介导的抗感染免疫功能，具有更优的安全性。可治疗的疾病包括中重度斑块状银屑病、银屑病关节炎、克罗恩病、溃疡性结肠炎。
代表药物：古塞奇尤单抗（Tremfya）、瑞莎珠单抗（Skyrizi）、替拉珠单抗（Ilumya）。瑞莎珠单抗在银屑病治疗中显示出极高的皮损清除率（PASI 90达80%以上，PASI 100达60%），给药间隔为每12周一次，是银屑病治疗的新标杆。
♀抗体君♀
Q8550 TSLP靶点介绍及代表药物？
TSLP（胸腺基质淋巴细胞生成素）是上皮来源的警报素细胞因子，通过结合TSLP受体（TSLPR/IL-7Rα复合物）激活树突状细胞、T细胞、2型固有淋巴细胞，驱动Th2型免疫应答。TSLP是哮喘、特应性皮炎、鼻息肉等2型炎症性疾病的上游关键因子，在气道炎症起始阶段发挥核心作用。TSLP抗体通过中和TSLP，阻断上游炎症启动信号，抑制下游多条炎症通路（Th2、Th17等），具有广泛的抗炎作用。可治疗的疾病包括中重度哮喘（嗜酸性粒细胞型和非嗜酸性粒细胞型）、特应性皮炎、慢性鼻窦炎伴鼻息肉。代表药物：Tezepelumab（Tezspire）是全球首个TSLP抗体，获批用于中重度哮喘，无论嗜酸性粒细胞水平均可获益，是首个不限于2型炎症的哮喘生物制剂，拓展了哮喘靶向治疗的适用人群。
♀抗体君♀
学则变 变则通 通则久
The above is the author's personal opinion
抗体药研发CMC知识8000问答|| 旨在梳理抗体药研发CMC知识，系统地掌握生物药研发全流程，欢迎关注 “抗体君” 微信公众号，让我们一起学习交流。在生物制药道路上，感恩您一路相伴！
往期精彩回顾Q&A 1-8000
抗体药研发CMC问答 [1~500]
抗体药研发CMC问答 [501~1000]
抗体药研发CMC问答 [1001~1500]
抗体药研发CMC问答 [1501~2000]
抗体药研发CMC问答 [2001~2500]
抗体药研发CMC问答 [2501~3000]
抗体药研发CMC问答 [3001~3500]
抗体药研发CMC问答 [3501~4000]
抗体药研发CMC问答 [4001~4500]
抗体药研发CMC问答 [4501~5000]
抗体药研发CMC问答 [5001~5500]
抗体药研发CMC问答 [5501~6000]
抗体药研发CMC问答 [6001~6500]
抗体药研发CMC问答 [6501~7000]
抗体药研发CMC问答 [7001~7500]
抗体药研发CMC问答 [7501~8000]Q&A 8001-10000 扫码添加“抗体君”微信学习
It always seems impossible until it’s done
更多学习资料请点击下面二维码加入群聊
“抗体君Club”
您的每一次的“关注”，我都认真的当作是爱！
免疫疗法临床研究抗体药物偶联物
2026-04-02
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
THE LANCET Infectious Diseases. Volume 26Number 4
柳叶刀传染病学 26卷 4期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
GoGoVax dispels hopes for gonorrhoea vaccination
GoGoVax让淋病疫苗的希望破灭
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329
COMMENT（述评）
2
Do the benefits of universal screening outweigh the harms?
全民筛查的益处是否大于害处？
Alanna N Gillespie,Emma Webb,Valerie Sung
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330
3
Chikungunya in Brazil: vaccination strategies informed by mathematical modelling
巴西基孔肯雅热：基于数学建模的疫苗接种策略
José Lourenço,Marta Giovanetti
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331
4
Chikungunya adolescent vaccination and the distinct risk–benefit landscapes
青少年接种基孔肯雅热疫苗及独特的风险-获益情况
Ernesto T A Marques,Simon Barratt-Boyes
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333
5
Circulation of clade Ib mpox outside of Africa—are we prepared?
非洲以外地区Ib分支猴痘的传播——我们准备好了吗？
Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334
6
I worked at WHO: the USA leaving will not make America healthier
我曾在世卫组织工作：美国退出不会让美国更健康
Krutika Kuppalli
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336
CORRESPONDENCE（读者来信）
7
Maternal views on RSV vaccination in the UK's second season
英国第二季呼吸道合胞病毒疫苗接种的产妇观点
Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209
8
Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters
利用COVID-19 LP.8.1 mRNA加强针克服免疫印记
Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2025; published online Nov 27.
https://doi.org/10.1016/S1473-3099(25)00605-X
《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
10
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
11
Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
12
Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
NEWSDESK（新闻台）
13
UK loses measles elimination status as cases rise
随着病例增加，英国失去麻疹消除地位
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215
14
Brazil launches implementation study of lenacapavir
巴西启动来那卡帕韦实施研究
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216
15
Clade Ib mpox in southwest Indian Ocean islands
西南印度洋岛屿出现Ib分支猴痘
Esther Nakkazi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217
16
EMA approves combined COVID-19 and flu mRNA vaccine
欧洲药品管理局批准COVID-19和流感联合mRNA疫苗
Talha Burki
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218
17
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219
OBITUARY（讣告）
18
Nicholas John White
尼古拉斯·约翰·怀特
Sanjeet Bagcchi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339
PROFILE（人物简介）
19
Katharina Kranzer—led by curiosity, committed to capacity
卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340
MEDIA WATCH（媒体观察）
Film（电影）
20
Leishmaniasis: a story of two continents
利什曼病：两个大陆的故事
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341
Book（书籍）
21
Finding your voice in a world of uncertainty
在不确定的世界中找到自己的声音
Carrie Fielden
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342
ARTICLES（论著）
22
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
GBD 2023下呼吸道感染和抗菌素耐药性协作组
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343
23
Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis
英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析
Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362
24
Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study
法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究
Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374
25
Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study
以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究
Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384
26
Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study
使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究
Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394
27
The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study
巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究
Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406
28
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果
Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417
29
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究
Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429
REVIEW（综述）
30
Autoantibodies in long COVID: a systematic review
长新冠中的自身抗体：一项系统综述
Fabian Wilhelm,Janne Cadamuro,Sylvia Mink
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220
31
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE）
Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231
PERSONAL VIEW（个人观点）
32
Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali
通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解
Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245
GRAND ROUND（大查房）
33
Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned
儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训
Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259
CLINICAL PICTURE（临床图像）
34
Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis
肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎
Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268
2026-03-26
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
THE LANCET Infectious Diseases. Volume 26Number 4
柳叶刀传染病学 26卷 4期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
GoGoVax dispels hopes for gonorrhoea vaccination
GoGoVax让淋病疫苗的希望破灭
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329
COMMENT（述评）
2
Do the benefits of universal screening outweigh the harms?
全民筛查的益处是否大于害处？
Alanna N Gillespie,Emma Webb,Valerie Sung
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330
3
Chikungunya in Brazil: vaccination strategies informed by mathematical modelling
巴西基孔肯雅热：基于数学建模的疫苗接种策略
José Lourenço,Marta Giovanetti
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331
4
Chikungunya adolescent vaccination and the distinct risk–benefit landscapes
青少年接种基孔肯雅热疫苗及独特的风险-获益情况
Ernesto T A Marques,Simon Barratt-Boyes
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333
5
Circulation of clade Ib mpox outside of Africa—are we prepared?
非洲以外地区Ib分支猴痘的传播——我们准备好了吗？
Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334
6
I worked at WHO: the USA leaving will not make America healthier
我曾在世卫组织工作：美国退出不会让美国更健康
Krutika Kuppalli
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336
CORRESPONDENCE（读者来信）
7
Maternal views on RSV vaccination in the UK's second season
英国第二季呼吸道合胞病毒疫苗接种的产妇观点
Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209
8
Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters
利用COVID-19 LP.8.1 mRNA加强针克服免疫印记
Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212
CORRECTIONS（更正）
9
Correction to Lancet Infect Dis 2025; published online Nov 27.
https://doi.org/10.1016/S1473-3099(25)00605-X
《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
10
Correction to Lancet Infect Dis 2026; 26: 343–61
《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
11
Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
12
Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214
NEWSDESK（新闻台）
13
UK loses measles elimination status as cases rise
随着病例增加，英国失去麻疹消除地位
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215
14
Brazil launches implementation study of lenacapavir
巴西启动来那卡帕韦实施研究
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216
15
Clade Ib mpox in southwest Indian Ocean islands
西南印度洋岛屿出现Ib分支猴痘
Esther Nakkazi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217
16
EMA approves combined COVID-19 and flu mRNA vaccine
欧洲药品管理局批准COVID-19和流感联合mRNA疫苗
Talha Burki
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218
17
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219
OBITUARY（讣告）
18
Nicholas John White
尼古拉斯·约翰·怀特
Sanjeet Bagcchi
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339
PROFILE（人物简介）
19
Katharina Kranzer—led by curiosity, committed to capacity
卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力
Tony Kirby
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340
MEDIA WATCH（媒体观察）
Film（电影）
20
Leishmaniasis: a story of two continents
利什曼病：两个大陆的故事
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341
Book（书籍）
21
Finding your voice in a world of uncertainty
在不确定的世界中找到自己的声音
Carrie Fielden
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342
ARTICLES（论著）
22
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
GBD 2023下呼吸道感染和抗菌素耐药性协作组
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343
23
Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis
英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析
Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362
24
Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study
法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究
Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374
25
Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study
以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究
Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384
26
Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study
使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究
Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394
27
The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study
巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究
Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406
28
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil
青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果
Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417
29
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究
Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429
REVIEW（综述）
30
Autoantibodies in long COVID: a systematic review
长新冠中的自身抗体：一项系统综述
Fabian Wilhelm,Janne Cadamuro,Sylvia Mink
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220
31
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)
登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE）
Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231
PERSONAL VIEW（个人观点）
32
Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali
通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解
Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245
GRAND ROUND（大查房）
33
Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned
儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训
Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259
CLINICAL PICTURE（临床图像）
34
Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis
肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎
Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú
The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268
100 项与 Sotrovimab 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Sotrovimab | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 新型冠状病毒感染 | 美国 | 2021-05-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 20 | (Sotrovimab) | 築齋鹹襯製膚膚艱鏇選(艱淵選廠艱淵願獵壓衊) = 齋鏇鏇艱製衊蓋簾糧醖 願淵獵夢餘淵鏇窪衊範 (觸淵顧顧範繭獵網鬱築, 18.59) 更多 | - | 2025-02-13 | ||
(Venipuncture) | 鬱積衊觸選齋鏇壓糧廠 = 糧製廠願鏇願鑰遞醖選 膚構願獵繭蓋齋遞簾淵 (艱鏇壓觸觸願憲築鬱艱, 選簾鬱糧遞選鹹鹽窪製 ~ 膚膚襯衊鬱獵繭簾繭鹽) 更多 | ||||||
临床4期 | 217 | 鬱鹽廠窪壓醖廠淵觸餘 = 蓋範糧鏇夢糧蓋簾淵選 簾窪夢糧醖範窪膚鹹積 (鏇網鬱餘遞觸觸繭選鹹, 獵襯選願鹽簾築窪淵壓 ~ 簾簾壓夢鬱選糧夢範艱) 更多 | - | 2024-10-15 | |||
临床1期 | 316 | (Part C: Cohort 1-Sotrovimab) | 窪遞顧網積蓋淵觸網糧 = 鏇網觸餘製廠窪願衊鑰 糧鏇淵淵壓艱網鬱製鏇 (醖齋範構簾觸鹹簾範構, 鏇窪膚窪醖獵鹽鏇膚選 ~ 獵遞觸構網鹹膚夢製艱) 更多 | - | 2024-09-19 | ||
(Part C: Cohort 2-Sotrovimab) | 築築鹽衊憲製憲鬱觸淵(襯憲鬱鏇膚鹽艱簾齋壓) = 齋選齋範膚壓網廠夢鑰 憲夢齋壓遞網餘鹽繭製 (壓襯壓範築餘築蓋鏇築, 鹹壓糧鹽獵淵淵鑰製襯 ~ 醖鬱選願願願選鏇淵膚) 更多 | ||||||
临床2期 | 93 | 顧淵鹽淵觸淵淵淵糧襯 = 構鏇糧蓋廠蓋鬱積鏇艱 願鹽網積膚鹽壓蓋獵簾 (艱蓋餘鹽積築鹹艱憲襯, 遞蓋餘夢醖構鬱糧網鹽 ~ 願獵觸鬱顧繭網範糧艱) 更多 | - | 2024-08-15 | |||
临床1期 | 48 | (Part 1: Sotrovimab 500 mg IV (Japanese)) | 選壓範鹽鏇膚範範憲淵(築觸願壓憲夢鑰憲選艱) = 積網獵築蓋築衊壓積鏇 淵糧壓遞鹽簾繭鹹觸選 (餘蓋遞觸壓顧鹹膚簾憲, 18.5) 更多 | - | 2024-06-07 | ||
(Part 1: Sotrovimab 500 mg IV (Caucasian)) | 選壓範鹽鏇膚範範憲淵(築觸願壓憲夢鑰憲選艱) = 衊鏇觸壓醖醖襯網網顧 淵糧壓遞鹽簾繭鹹觸選 (餘蓋遞觸壓顧鹹膚簾憲, 13.8) 更多 | ||||||
临床2期 | 8 | (Cohort A: Sotrovimab Intravenous (IV) (6 to Less Than [<] 12 Years)) | 衊鏇網繭蓋蓋齋鬱蓋選(襯艱齋鏇鹹繭範鬱觸築) = 積獵鹽顧遞壓選選鬱齋 廠築醖網繭繭觸壓簾築 (衊鏇構築願顧衊鑰壓艱, 27.6) 更多 | - | 2024-01-03 | ||
(Cohort A: Sotrovimab Intravenous (IV) (12 to Less Than [<] 18 Years)) | 衊鏇網繭蓋蓋齋鬱蓋選(襯艱齋鏇鹹繭範鬱觸築) = 醖製鏇蓋廠衊鬱膚艱鑰 廠築醖網繭繭觸壓簾築 (衊鏇構築願顧衊鑰壓艱, 28.5) 更多 | ||||||
临床3期 | 367 | (VIR-7831 Plus SOC) | 簾淵鏇夢餘廠齋遞範築 = 積觸壓簾鬱蓋齋遞淵夢 醖鹹積鏇鏇觸糧淵鏇餘 (簾願遞壓觸廠獵醖範鏇, 蓋壓鑰繭遞齋夢網築衊 ~ 夢遞糧廠醖觸襯襯築齋) 更多 | - | 2023-11-18 | ||
Placebo+Remdesivir (Placebo Plus SOC) | 簾淵鏇夢餘廠齋遞範築 = 衊繭獵鏇繭壓膚壓糧鹽 醖鹹積鏇鏇觸糧淵鏇餘 (簾願遞壓觸廠獵醖範鏇, 齋鏇夢鏇構夢範鬱齋淵 ~ 醖選繭願餘壓膚築淵鏇) 更多 | ||||||
临床2/3期 | 1,057 | 鬱觸廠蓋鹹鏇餘衊餘齋(遞餘製憲淵齋衊積憲獵) = 範淵壓鑰鏇築廠範鹽積 憲構糧簾鹽遞觸鹽蓋蓋 (糧願窪憲壓顧膚觸網觸 ) | 积极 | 2023-09-13 | |||
Placebo | 鬱觸廠蓋鹹鏇餘衊餘齋(遞餘製憲淵齋衊積憲獵) = 範網鬱廠壓選齋鑰齋製 憲構糧簾鹽遞觸鹽蓋蓋 (糧願窪憲壓顧膚觸網觸 ) | ||||||
临床4期 | 4,571 | (Lilly Bamlanivimab) | 餘鏇築簾艱衊醖餘餘膚(夢糧鬱餘積衊製餘鏇遞) = 鑰獵構夢衊淵襯齋蓋範 憲選範製夢醖齋衊製餘 (餘廠願餘選鏇鹽積糧願, 築壓艱鹹獵網簾獵網鹹 ~ 鏇鹹蓋淵醖廠築糧遞顧) 更多 | - | 2023-06-15 | ||
(Regeneron Casirivimab + Imdevimab) | 餘鏇築簾艱衊醖餘餘膚(夢糧鬱餘積衊製餘鏇遞) = 衊夢糧憲壓鏇淵蓋膚觸 憲選範製夢醖齋衊製餘 (餘廠願餘選鏇鹽積糧願, 夢餘選廠遞醖觸衊鏇廠 ~ 鹹遞壓網簾範醖糧築獵) 更多 | ||||||
临床3期 | 1,065 | (Main Study: Sotrovimab 500 mg IV) | 餘築膚夢蓋夢窪築糧淵 = 糧積製淵衊鹽鹹窪鹹積 鑰鏇醖壓簾壓窪範積餘 (獵獵願願鑰鹹簾廠壓選, 簾獵築艱選襯窪鏇鏇壓 ~ 獵鑰鏇艱鬱餘積餘選鑰) 更多 | - | 2023-05-26 | ||
(Main Study: Sotrovimab 500 mg IM) | 餘築膚夢蓋夢窪築糧淵 = 壓憲廠願選願鏇積膚衊 鑰鏇醖壓簾壓窪範積餘 (獵獵願願鑰鹹簾廠壓選, 齋餘襯築鹹鬱壓積餘膚 ~ 觸積蓋壓淵鑰憲鹽範艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用